Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1^st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.

Brexpiprazole: A Newly Approved Atypical Antipsychotic Agent

Brexpiprazole - Mechanism of Action and Clinical Application

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

Rexulti (Brexpiprazole) - PSYCH-MENTAL HEALTH HUB

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

Full article: In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole

FDA approves Rexulti for schizophrenia, depression in schizophrenia

Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human

FDA Approves sNDA for Rexulti for Adolescents With Schizophrenia

Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for #Alzheimers agitation. Will it find its way to #Parkinsons? Depends on if it makes motor symptoms significantly worse. It works on D2